Another study focusing on the clinical implications of serum VEGF-A and IL-1 β in patients with advanced non-small-cell lung cancer (NSCLC) revealed that high levels of those cytokines were related to shorter overall survival, revealing them as significant prognostic factors [103]. Here, VEGFA is linked to non-small cell lung carcinoma.